 |
|
 Even a relatively small weight loss of 5% to 10% of initial body weight lowers levels of triglycerides, decreases total cholesterol and increases levels of HDL cholesterol — thereby improving the ratio of LDL cholesterol to HDL cholesterol and reducing the risk of atherosclerosis.5 In one study, three times as many patients (25% on XENICAL plus diet versus 8% on placebo plus diet, P<0.001) lost 10% or more of their body weight from randomization (mean: 31 lbs; range: 18 to 67 lbs).20,57 XENICAL is indicated for obesity management in patients with an initial body mass index (BMI) of 30 or more and in patients with a BMI of 27 or more in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia). After 6 months, 72% of patients lost 5% or more of their initial body weight, with a mean loss of 23 lbs. Weight loss with XENICAL plus diet has been shown to significantly reduce total and LDL cholesterol levels, increase HDL cholesterol and improve the LDL/HDL ratio.15 Specific Health Benefits: Population with Abnormal (Untreated) Risk Factors at Randomization Weight Loss with XENICAL Plus Diet: Improved Lipid Levels The changes from randomization following 1-year treatment in the population with abnormal lipid levels (LDL>130 mg/dL, LDL/HDL >3.5, HDL <35 mg/dL) were greater for patients on XENICAL plus diet compared to patients on placebo plus diet with respect to LDL cholesterol (-7.83% vs. 1.14%) and the LDL/HDL ratio (-0.64 vs. 0.46). HDL cholesterol increased in the placebo group by 20.1% and in the XENICAL group by 18.8%. The chart below shows that treatment with XENICAL plus diet improved LDL Cholesterol levels in patients with baseline values >130 mg/dL compared to placebo plus diet. 
The long-term effects of XENICAL (orlistat) on morbidity and mortality associated with obesity have not been established. Managing Patients with Obesity-Related Comorbidities More about Obesity as a Clinical Condition |
|
|
|||||
|
|
||||||||
|
|
|
|||||||
|
|
|
|
|
|
||||
|
|
|
|
||||||
